Evidence types
Observational study articles covering real-world data, cohort studies, registries, and non-interventional IBD research.
40 articles
Comparative real-world data may help patients and clinicians weigh expected benefits and risks of risankizumab versus ustekinumab in Crohn’s disease, including effects on steroid-free remission and fistula healing.
Compares widely used modelled GBD rates with population-based observations and finds they are not interchangeable for country-year estimates—important for research, surveillance, and policy that rely on these numbers.
Pregnant people with Crohn’s disease are often prescribed disease‑modifying therapies, yet clinical trial data in pregnancy are limited. Understanding real‑world medication use and potential drug–drug interactions helps...
If confirmed, the results suggest early-life exposures that perturb the gut microbiome may influence later risk of spondyloarthritis, which could be relevant for parents and clinicians weighing risks and benefits of...
Patients and clinicians considering sequencing of advanced UC therapies may care because this study reports differences in how long patients stayed on second-line treatment depending on the order of anti-TNF agents and...
Cure8 indexed source-provided abstract text from National Center for Health Statistics (U.S.), but this record did not meet the threshold for a full Cure8 brief. It is tagged for Inflammatory bowel disease and Research...
Hospitalizations for Crohn’s and ulcerative colitis in Brazil increased from 2015–2024, which may affect access to care, costs, and planning of IBD services. Patients and clinicians should be aware of regional and...
If true, the study suggests that long-term air pollution exposure may raise the risk of developing IBD and that greater adherence to a plant-based diet could be linked with a lower pollution-related risk. That may be...
This study examines whether patterns of body size from birth through adulthood add information about IBD risk beyond adult BMI and genetic susceptibility. Results suggest life-course size trajectories may be more related...
Measuring mucosal healing across the whole gut with stool markers, ultrasound, and capsule endoscopy may give a clearer picture of whether biologic treatment is working and help guide decisions about continuing or...
This study analyzes thousands of adverse event reports for ustekinumab in Crohn’s disease and highlights infections plus possible cardiovascular and neuropsychiatric signals that clinicians and patients may want to...
This study addresses whether removing the appendix changes long-term UC outcomes. People with UC or their clinicians might expect surgery to alter disease course; these real-world data suggest it generally does not for...
This study highlights that people who go on to develop myasthenia gravis had higher rates of other autoimmune diagnoses in the years beforehand, which may be relevant for clinicians tracking autoimmune comorbidity...
If you are Ashkenazi Jewish or care for someone who is, research shows higher group-level risk for Crohn’s disease, ulcerative colitis and lactose intolerance—so awareness and early evaluation for gut symptoms may be...
Surgery for IBD has become less common since modern biologic therapies, but a noticeable number of patients—especially with Crohn’s disease and poor nutrition—still progress to operations. Understanding who remains at...
People with IBD may have a higher-than-expected rate of biopsy-confirmed celiac disease in this Northern Indian cohort, and standard anti-tTG blood tests can be falsely positive in IBD. Confirmatory duodenal biopsy is...
People with PsD or IBD — or both — may develop the other condition years later, and the order of diagnoses appears linked to timing of the second disease and to differences in mortality for some groups. That could affect...
People with both IBD and another immune-mediated disease (psoriatic disease) had more hospital admissions and higher inpatient costs over ten years in this population.
People with IBD or other autoimmune diseases are often concerned that vaccines might work less well for them.
People on biologic therapy who are not responding to standard doses may benefit from dose escalation — this study suggests escalation is common in routine care and linked with improved objective and patient‑reported...
Methotrexate is commonly used in IBD, often with biologics, but real‑world data on how long patients stay on it, typical dosing, and safety in large contemporary cohorts are limited.
Earlier use of advanced therapies and less steroid exposure could affect long-term outcomes and side-effect risk for people with newly diagnosed IBD. The study also identifies lower use of advanced therapies among...
Knowing the makeup and regional distribution of IBD specialists helps identify gaps in care access and guide training or policy efforts to expand specialist capacity in underserved areas.
Patients and clinics are still deciding how much care can be done remotely. Knowing who prefers in-person versus remote visits helps tailor care so patients receive the visit type they need and want, and supports...
The study shows that more children worldwide are living with early-onset IBD even as mortality has fallen, and it highlights persistent socioeconomic disparities—important for families and clinicians tracking pediatric...
This large, population-based study tests whether exposure to outdoor artificial light at night is linked to getting IBD or to later health-care use. Understanding environmental factors that might influence IBD risk or...
Shows real-world long-term outcomes in a large Chinese UC cohort and highlights that baseline disease activity predicts need for escalation and colectomy risk; points to opportunities to improve treat-to-target care.
A coordinated national research network can accelerate studies that matter to people with IBD—like tracking real-world disease patterns, testing diet and psychosocial approaches, improving monitoring with biomarkers and...
Patients, families, and clinicians may care because the study shows pediatric-onset IBD is more often Crohn's and that children begin advanced therapies earlier than adults. The adult persistence data for vedolizumab and...
Lower hospitalization rates suggest upadacitinib may reduce severe disease events that require inpatient care, which matters to patients and clinicians aiming to avoid hospital stays and complications. Large real-world...
This study quantifies the large NHS and societal costs of Crohn’s disease and ulcerative colitis in the UK and highlights that ongoing management and maintaining remission are major drivers of expense.
This large real-world study suggests GLP-1 receptor agonists used in adults with Crohn’s disease and obesity were associated with lower healthcare use and lower subsequent TNF inhibitor use at 1 and 5 years, findings...
This study reports real-world effectiveness of risankizumab for refractory Crohn's disease, showing many patients achieved steroid-free remission. The results are relevant for people weighing treatment options after...
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
If EBV exposure is linked to higher Crohn’s risk, it could point to new avenues for understanding who develops IBD and why. For people with Crohn’s or at risk for it, the finding helps explain ongoing research into...
If EBV infection raises Crohn's risk, it could point to new causes and therapeutic targets. Many people with or at risk for IBD will want to know whether viral exposure plays a role in their disease or in prevention...
If EBV exposure increases the risk of later Crohn's disease, it could help explain one environmental trigger for IBD and point to new research directions for prevention or treatment. Patients may be interested because...
The study explores whether larger spleen size might play a causal role in the risk of ulcerative colitis or Crohn’s disease, using genetic data to reduce confounding. If a causal link exists, spleen volume could be a...
Based on the title and source metadata, this appears to be an observational study related to Research and clinical trials. The original article is from msn.com.
Based on the title and source metadata, this appears to be an observational study related to Research and clinical trials. The original article is from msn.com.
